Your browser doesn't support javascript.
loading
Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland.
McKeigue, Paul M; Burgul, Raj; Bishop, Jen; Robertson, Chris; McMenamin, Jim; O'Leary, Maureen; McAllister, David A; Colhoun, Helen M.
Afiliación
  • McKeigue PM; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, Scotland, UK.
  • Burgul R; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, Scotland, UK.
  • Bishop J; Forth Valley Royal Hospital, Larbert, FK5 4WR, Scotland, UK.
  • Robertson C; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, Scotland, UK.
  • McMenamin J; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, Scotland, UK.
  • O'Leary M; Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond Street, Glasgow, G1 1XQ, Scotland, UK.
  • McAllister DA; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, Scotland, UK.
  • Colhoun HM; Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, Scotland, UK.
BMC Infect Dis ; 21(1): 1275, 2021 Dec 20.
Article en En | MEDLINE | ID: mdl-34930153
BACKGROUND: To investigate the association of primary acute cerebral venous thrombosis (CVT) with COVID-19 vaccination through complete ascertainment of all diagnosed CVT in the population of Scotland. METHODS: Case-crossover study comparing cases of CVT recently exposed to vaccination (1-14 days after vaccination) with cases less recently exposed. Cases in Scotland from 1 December 2020 were ascertained through neuroimaging studies up to 17 May 2021 and diagnostic coding of hospital discharges up to 28 April 2021, linked to national vaccination records. The main outcome measure was primary acute CVT. RESULTS: Of 50 primary acute CVT cases, 29 were ascertained only from neuroimaging studies, 2 were ascertained only from hospital discharges, and 19 were ascertained from both sources. Of these 50 cases, 14 had received the Astra-Zeneca ChAdOx1 vaccine and 3 the Pfizer BNT162b2 vaccine. The incidence of CVT per million doses in the first 14 days after vaccination was 2.2 (95% credible interval 0.9 to 4.1) for ChAdOx1 and 1 (95% credible interval 0.1 to 2.9) for BNT162b2. The rate ratio for CVT associated with exposure to ChAdOx1 in the first 14 days compared with exposure 15-84 days after vaccination was 3.2 (95% credible interval 1.1 to 9.5). CONCLUSIONS: These findings support a causal association between CVT and the AstraZeneca vaccine. The absolute risk of post-vaccination CVT in this population-wide study in Scotland was lower than has been reported for populations in Scandinavia and Germany; the explanation for this is not clear.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trombosis de la Vena / COVID-19 Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trombosis de la Vena / COVID-19 Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article